Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.79 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geldanamycin SCHEMBL16669998 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL14626015 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL13928050 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL14399626 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL254191 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL12671560 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL254142 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL17973297 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL14583125 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL13101681 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32930 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746898-A2 | IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4739678-A2 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | Memorial Sloan Kettering Cancer Center (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260125647-A1 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727558-A1 | NOVEL METHOD EMPLOYING ANTIBIOTICS WITH ACCRETION TO APATITE COATED IMPLANTS PREVENTING BACTERIAL ATTACHMENT AND INFECTION | Moroxite I AB (SE) | 2026-04-22 | — | — | EP | claimed |
| EP-4729525-A1 | NEWLY SYNTHESIZED BORON-NITROGEN HETEROCYCLES AND THEIR CONJUGATES WITH PHARMACEUTICALLY UTILIZABLE SUBSTANCES | Julius-Maximilians-Universität Würzburg (DE) | 2026-04-22 | — | — | EP | claimed |
| WO-1999021552-A1 | USE OF NON-IMMUNOSUPPRESSIVE COMPOUNDS FOR PROMOTING NERVE REGENERATION | OREGON HEALTH SCIENCES UNIVERSITY (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1998051702-A1 | METHODS AND COMPOSITIONS FOR DESTRUCTION OF SELECTED PROTEINS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-11-19 | — | — | WO | claimed |
| CN-1189340-A | Novel grand spectrum anti-virus application of Gerd mycomycin | TAO PEIZHEN (CN) | 1998-08-05 | — | — | CN | claimed |
| WO-1998029110-A2 | FORMULATION AND METHOD FOR TREATING NEOPLASMS BY INHALATION | BATTELLE MEMORIAL INSTITUTE (US) | 1998-07-09 | — | — | WO | claimed |
| EP-0828418-A1 | INDUCEMENT OF THERMOTOLERANCE WITH BENZOQUINONOID ANSAMYCINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-18 | — | — | EP | claimed |
| US-5626757-A | RESOLUTION OF ENANTIOMORPHS BY ELECTROPHORESIS AND CHROMATOGRAPHY | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 1997-05-06 | — | — | US | claimed |
| WO-1996034525-A1 | INDUCEMENT OF THERMOTOLERANCE WITH BENZOQUINONOID ANSAMYCINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-11-07 | — | — | WO | claimed |
| EP-0664702-A1 | TUMORICIDAL ACTIVITY OF BENZOQUINONOID ANSAMYCINS AGAINST PROSTATE CANCER AND PRIMITIVE NEURAL MALIGNANCIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994008578-A2 | TUMORICIDAL ACTIVITY OF BENZOQUINONOID ANSAMYCINS AGAINST PROSTATE CANCER AND PRIMITIVE NEURAL MALIGNANCIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-04-28 | — | — | WO | claimed |
| US-4261989-A | Geldanamycin derivatives and antitumor drug | KAKEN CHEMICAL CO. LTD. (JP) | 1981-04-14 | — | — | US | claimed |